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| INTRODUC TI ON
According to a recently published report of cancer incidence and mortality in China, lung cancer is still the most common cancer nationwide, and is the leading cause of cancer death. Non-small cell lung cancer accounts for approximately 85% of all lung cancers, 4 which are relatively insensitive to chemotherapy compared to small cell lung cancer. For NSCLC patients with gene mutations, such as EGFR or ALK mutations, targeted therapy has already become the first line treatment. 5 However, acquired resistance to targeted drugs is inevitable, and chemotherapeutic agents or immune checkpoint inhibitors will be used as alternative drugs after the failure of targeted therapy or combined drugs in the treatment. [6] [7] [8] As genotyping becomes increasingly common, it is necessary to understand the sensitivity of patients with different mutation types to different chemotherapeutic agents or immune checkpoints inhibitors.
Due to the short history of conventional genotyping, there are few studies that have reported on the relationship between different genotypes and non-targeted drugs. However, as alternatives to actual drug efficacy indicators, some known drug resistance markers or sensitive markers can predict the efficacy of certain drugs. For example, high levels of ribonucleotide reductase subunit M1 (RRM1) have been associated with resistance to gemcitabine. 9 Programmed death-ligand 1 (PD-L1) positive expression enhanced the efficacy of nivolumab in patients with advanced non-squamous NSCLC.
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Our study analyzes the relationship between different genotypes and the expression of some known predictive markers, thus providing information critical for individualization of immunotherapy and chemotherapy. 
| MATERIAL S AND ME THODS

| Patients and samples
| Next-generation sequencing-based genomic profiling
The specimens were reviewed to ensure tissue adequacy (>20% were grouped according to the mutation with highest abundance in the patient. According to the gene mutations, a low expression rate (ERCC1, RRM1, TS and β-tubulin III) or a positive rate (PD-L1) of the predictive markers were also calculated in each subgroup.
| Histological analysis
The overall percentage was used as a reference cut-off for each sensitivity marker.
| Pilot validation
Another 21 patients with wild-type (pan-negative) advanced NSCLC were divided into 2 groups based on the treatment. Group A used anti-microtubule agents, such as docetaxel or paclitaxel, while group B used antimetabolic agents, such as gemcitabine or pemetrexed.
The depth of response (DoR) and the objective response rate (ORR)
were calculated as tumor remission indicators to show the drug efficacy.
| Statistical analysis
Statistical analysis was performed using R studio 19.0 and IBM SPSS 
| RE SULTS
| Baseline characteristics
This study included 438 male and 347 female NSCLC patients, 
| Distribution of different mutations
A total of 498 (63.4%) patients had at least 1 driver gene alteration; 34 patients had compound mutations. Only the mutation with highest abundance is considered for patient classification (Table S1 ). The prevalence of each benchmark driver mutation is shown in Table 2 .
Wild-type patients have the highest proportion, 36.6%, followed by EGFR L858R, 23.2%, and EGFR 19del, 21.4%.
| Correlation between driver mutations and predictive markers
Correlation between driver mutations and predictive markers is summarized in Figure 2 and 
| Pilot validation of sensitivity prediction
Anti-microtubule drugs, rather than anti-metabolic agents, were consistent with recommendation in wild-type patients. Group A has 10 advanced NSCLC patients, while group B has 11 patients. There was no significant difference in gender (male 10/8, 
| D ISCUSS I ON
All previous treatment strategies for NSCLC patients were based on the whole population. It is now known that genotyping determines
The examples representing different expression levels of ERCC1, RRM1, TS, β-tubulin III and PD-L1. −~+, ++ and +++ measure the expression of ERCC1, RRM1, TS and β-tubulin III. 1%, 50% and 100% for PD-L1 The present study assessed the relationship between genotyping for 8 important driver genes and some outcomes of sensitivity markers of chemotherapy and immunotherapy in a large sample of NSCLC patients. EGFR mutations were still the most common gene alterations in NSCLC patients, followed by RAS and ALK. The genotyping results agreed with previous studies in the prevalence of driver mutations in Chinese NSCLC patients. 12 The low expression rate of ERCC1, RRM1, TS and β-tubulin III, and the PD-L1 positive rate, differing from other studies, might be due to, for instance, different races, proportions of histology and stages. [13] [14] [15] In particular, the issue of ERCC1 isoform and PD-L1 antibody selection for IHC is worth mentioning. and there is still no consensus on which is the optimal PD-L1 detecting antibody. In the initial stage of our PD-L1 study, the pathology department of our hospital used antibody SP142 for all NSCLC patients. The aim of the present study was to detect the expression of PD-L1 for the whole population to obtain a general level rather than for the expression of one certain patient to select drugs. Therefore, we consider SP142 to be reasonable on that basis.
Some previous studies have demonstrated the relationship between predictive markers and certain chemo agents or targeted drugs. The results revealed that tumor histology also had an impact on their correlation. Low expression of ERCC1 can predict higher objective response of platinum-based therapy in NSCLC patients with better outcome, 18, 19 and squamous patients seemed to benefit more. 20 Patients with high RRM1 expression showed resistance to gemcitabine. 9 A low level of TS expression was related to clinical benefit from pemetrexed therapy. 21 Combining data from 10 studies supported that β-tubulin III could be a predictive factor for sensitivity to chemotherapy regimens containing taxanes or vinorelbine, the ORR of the chemotherapy was significantly higher in patients with low/negative expression. 22 PD-L1 expression enhanced the efficacy of nivolumab. Note: Low expression of ERCC1, RRM1, TS and β-tubulin III indicate better sensitivity to platinum, gemcitabine, pemetrexed and anti-microtubule agents, respectively, while positive/higher PD-L1 expression indicates better sensitivity to PD-(L)1 inhibitors. The percentage of favorable expression of each marker (low ERCC1, low RRM1, low TS, low β-tubulin III and positive PD-L1) in overall population is used as the cut-off value. ERCC1, excision repair cross-complementation group 1; fus, fusion; mut, mutation; PD-(L)1, programmed death-ligand 1; RRM1, ribonucleotide reductase subunit M1; TS, thymidylate synthase.
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F I G U R E 2 Correlation between driver mutations and predictive markers
a
The rate was higher than the general level, and the drugs in the last column were considered sensitive to patients with certain genotype. b Green shades mean that the rate was higher than the general level.
and taxanes might be the most sensitive chemo agents. For EGFRmutant patients, PD-(L)1 inhibitors were not recommended, 26 while patient with KARS, BRAF and MET mutations benefit more from immune checkpoint inhibitors than EGFR, ALK and RET patients. 25, 28 With the common practice of gene mutation detection, there will be more evidence from qualified clinical studies to support these results.
Our study has provided enlightenment for clinical practice. On the one hand, detection of gene mutations can help in selecting the best available drugs for targeted therapy. On the other hand, for the patients with drug resistance after targeted cancer therapies and without specific targeted therapies, the analysis of the predictive markers of chemotherapy and immunotherapy efficacy can provide an important reference to choose the optimal chemotherapy and assess whether it is suitable for immunotherapy. In addition, the results explain why patients differ in sensitivity to various drugs from the perspective of gene mutations.
It is noteworthy that there is no clear conclusion on the relationship between predictive markers and chemotherapy efficacy; large randomized studies are needed to determine their predictive value in different settings and tumors. And for our study, there is still a need for follow-up studies to analyze the data of patients receiving these drugs and to verify the clinical significance of this study. In the future, precise treatment will be the key point in drug research and development, and more specific and selective biomarkers will be identified. Furthermore, a feasible method of continuous dynamic detection of biomarkers, especially liquid biopsy, will play an important role both in drug guidance and resistance. Thus, patients receiving individualized treatment will benefit more.
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